Douglas T. Dieterich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Douglas T. Dieterich has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Kian Bichoupan
Kian Bichoupan, Neeta Tandon, Valerie Martel-Laferriere, Neal M Patel, David Sachs, Michel Ng, Emily A Schonfeld, Alexis Pappas, James Crismale, Alicia Stivala, Viktoriya Khaitova, Donald Gardenier, Michael Linderman, William Olson, Ponni V Perumalswami, Thomas D Schiano, Joseph A Odin, Lawrence U Liu, Douglas T Dieterich, Andrea D Branch, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, Icahn Medical Instititute, New York, NY 10029, United States
3 shared publications - Hussien Elsiesy
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
2 shared publications - Jeffrey Fessel
Department of Medicine, University of California, 2069 Filbert Street, San Francisco, CA 94123, USA
2 shared publications Kian Bichoupan
Icahn School of Medicine at the Mount Sinai School of Medicine, New York, USA
2 shared publications- Mark S. Sulkowski
Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland
2 shared publications - Tatyana Kushner
Department of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York, USA
2 shared publications
Latest Publications
- Open Access
- 8 September 2026
- Published by Elsevier in JHEP Reports
Screening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis
- 8 September 2026
- Published by Elsevier in JHEP Reports
Open AccessScreening for Metabolic Dysfunction-Associated Steatohepatitis in Adults with Type 2 Diabetes in the U.S. and 5 European Countries: A Cost-Utility Analysis
- 17 August 2023
- Published by Elsevier in Clinics in Liver Disease
- Vol. 28 (1) , 143-155
Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis
- 17 August 2023
- Published by Elsevier in Clinics in Liver Disease
- Vol. 28 (1) , 143-155
Phenotypes of Primary Sclerosing Cholangitis and Differential Diagnosis
- Open Access
- 22 June 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.
HDV, which coinfects individuals living with HBV, is the most aggressive form of viral hepatitis. Compared with hepatitis B monoinfection, hepatitis delta is associated with more rapid progression to cirrhosis and an increased risk of liver cancer and death. Despite being a major contributor to hepatitis B-associated liver disease, hepatitis delta remains largely unknown to the general public, health care providers, and at-risk communities. Given the widespread lack of awareness and underdiagnosis of hepatitis delta in the US, the American Liver Foundation (ALF) and the Hepatitis B Foundation (HBF) convened a virtual Hepatitis Delta Roundtable Meeting on April 21 and 22, 2022. The Roundtable Panel included persons living with hepatitis delta, caregivers, liver disease specialists, primary care providers, state and federal public health professionals, and community-based organizations. The Panel identified several major challenges surrounding hepatitis delta, including a lack of awareness of hepatitis delta among the public and health care providers; complex risk-based testing protocols; a lack of accurate prevalence data; limited data on linkage to care; and inadequate communications among stakeholders. Potential strategies to address these challenges include improving and expanding education for different audiences; advocating for simplified protocols for hepatitis B screening with hepatitis delta reflex testing; expanding surveillance for hepatitis delta; requiring automated reporting and national notification; improving data sharing for research; and enhancing communications around hepatitis delta. The recent CDC recommendations for universal adult screening and vaccination against hepatitis B and the anticipated availability of new therapies for hepatitis delta present a unique opportunity to focus attention on this dangerous virus. The Roundtable Panel calls for urgent action to make significant progress in addressing hepatitis delta among individuals living with hepatitis B.
- 22 June 2023
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 7 (7)
Open AccessAdvancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.
HDV, which coinfects individuals living with HBV, is the most aggressive form of viral hepatitis. Compared with hepatitis B monoinfection, hepatitis delta is associated with more rapid progression to cirrhosis and an increased risk of liver cancer and death. Despite being a major contributor to hepatitis B-associated liver disease, hepatitis delta remains largely unknown to the general public, health care providers, and at-risk communities. Given the widespread lack of awareness and underdiagnosis of hepatitis delta in the US, the American Liver Foundation (ALF) and the Hepatitis B Foundation (HBF) convened a virtual Hepatitis Delta Roundtable Meeting on April 21 and 22, 2022. The Roundtable Panel included persons living with hepatitis delta, caregivers, liver disease specialists, primary care providers, state and federal public health professionals, and community-based organizations. The Panel identified several major challenges surrounding hepatitis delta, including a lack of awareness of hepatitis delta among the public and health care providers; complex risk-based testing protocols; a lack of accurate prevalence data; limited data on linkage to care; and inadequate communications among stakeholders. Potential strategies to address these challenges include improving and expanding education for different audiences; advocating for simplified protocols for hepatitis B screening with hepatitis delta reflex testing; expanding surveillance for hepatitis delta; requiring automated reporting and national notification; improving data sharing for research; and enhancing communications around hepatitis delta. The recent CDC recommendations for universal adult screening and vaccination against hepatitis B and the anticipated availability of new therapies for hepatitis delta present a unique opportunity to focus attention on this dangerous virus. The Roundtable Panel calls for urgent action to make significant progress in addressing hepatitis delta among individuals living with hepatitis B.
- Open Access
Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts with hepatitis C or HIV where early treatment is recommended in all infected patients, regardless of end-organ damage. This narrative review aims to provide an overview of data on the early initiation of antiviral treatment and its related potential economic impact. Literature searches were performed using PubMed and abstracts from international liver congresses (2019–2021). Data on risk of disease progression and HCC and the impact of antiviral treatment in currently ineligible patients were summarized. Cost-effectiveness data on early antiviral treatment initiation were also collated. Accumulating molecular, clinical, and economic data suggest that early initiation of antiviral treatment could save many lives through HCC prevention in a highly cost-effective manner. In light of these data, we consider several alternative expanded treatment strategies that might further a simplified ‘treatment as prevention’ approach.
Open AccessEvidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts with hepatitis C or HIV where early treatment is recommended in all infected patients, regardless of end-organ damage. This narrative review aims to provide an overview of data on the early initiation of antiviral treatment and its related potential economic impact. Literature searches were performed using PubMed and abstracts from international liver congresses (2019–2021). Data on risk of disease progression and HCC and the impact of antiviral treatment in currently ineligible patients were summarized. Cost-effectiveness data on early antiviral treatment initiation were also collated. Accumulating molecular, clinical, and economic data suggest that early initiation of antiviral treatment could save many lives through HCC prevention in a highly cost-effective manner. In light of these data, we consider several alternative expanded treatment strategies that might further a simplified ‘treatment as prevention’ approach.
- Open Access
- 13 April 2023
- Published by Mattioli1885 in La Medicina del Lavoro
- Vol. 114 (2) , e2023016
Prevalence of and Risk Factors for Hepatitis C Virus Infection in World Trade Center Responders
Background: The risk of hepatitis C virus (HCV) infection among emergency responders exposed to human remains, blood/bodily fluids, and/or sewage is unknown. Methods: A cross-sectional study of 3871 World Trade Center General Responder Cohort (WTCGRC) members followed at the Icahn School of Medicine at Mount Sinai, born from 1945-1965, and recruited from 2016-2018 were tested for HCV infection, and prevalence was compared to National Health and Nutrition Examination Survey data from 2003 to 2012. A nested case-control study compared 61 HCV antibody positive cases to 2571 controls. Multivariable logistic regression models adjusting for time of birth, traditional HCV risk factors, and type of work at the World Trade Center (WTC) site, determined if contact with human remains, blood/bodily fluids, and/or sewage at the WTC site was associated with HCV infection. Results: The age-standardized point prevalence of HCV infection among WTCGRC members was 2.98% [95% CI (2.39, 3.56)] and in the US population was 3.33% [95% CI (2.54, 4.11)] [% difference = 0.35%, 95% CI (- 0.31%, 1.01%), P=0.47]. In separate multivariable models, adjusting for possible confounders, contact with human remains was not associated with HCV infection [OR = 1.10, 95%CI(0.63, 1.91), P = 0.74)], contact with blood and/or bodily fluids was not associated with HCV infection [OR = 1.45, 95%CI(0.82, 2.56), P = 0.20], and contact with sewage was significantly associated with HCV infection [OR = 1.72, 95%CI(1.00, 2.98), P = 0.05]. Conclusion: Contact with sewage may increase the risk of HCV infection.
- 13 April 2023
- Published by Mattioli1885 in La Medicina del Lavoro
- Vol. 114 (2) , e2023016
Open AccessPrevalence of and Risk Factors for Hepatitis C Virus Infection in World Trade Center Responders
Background: The risk of hepatitis C virus (HCV) infection among emergency responders exposed to human remains, blood/bodily fluids, and/or sewage is unknown. Methods: A cross-sectional study of 3871 World Trade Center General Responder Cohort (WTCGRC) members followed at the Icahn School of Medicine at Mount Sinai, born from 1945-1965, and recruited from 2016-2018 were tested for HCV infection, and prevalence was compared to National Health and Nutrition Examination Survey data from 2003 to 2012. A nested case-control study compared 61 HCV antibody positive cases to 2571 controls. Multivariable logistic regression models adjusting for time of birth, traditional HCV risk factors, and type of work at the World Trade Center (WTC) site, determined if contact with human remains, blood/bodily fluids, and/or sewage at the WTC site was associated with HCV infection. Results: The age-standardized point prevalence of HCV infection among WTCGRC members was 2.98% [95% CI (2.39, 3.56)] and in the US population was 3.33% [95% CI (2.54, 4.11)] [% difference = 0.35%, 95% CI (- 0.31%, 1.01%), P=0.47]. In separate multivariable models, adjusting for possible confounders, contact with human remains was not associated with HCV infection [OR = 1.10, 95%CI(0.63, 1.91), P = 0.74)], contact with blood and/or bodily fluids was not associated with HCV infection [OR = 1.45, 95%CI(0.82, 2.56), P = 0.20], and contact with sewage was significantly associated with HCV infection [OR = 1.72, 95%CI(1.00, 2.98), P = 0.05]. Conclusion: Contact with sewage may increase the risk of HCV infection.
- Open Access
- 14 October 2022
- Published by Elsevier in Gastro Hep Advances
- Vol. 2 (2) , 209-218
It Is Time for a Simplified Approach to Hepatitis B Elimination
- 14 October 2022
- Published by Elsevier in Gastro Hep Advances
- Vol. 2 (2) , 209-218
Open AccessIt Is Time for a Simplified Approach to Hepatitis B Elimination
- 26 January 2021
- Published by Taylor & Francis in Future Virology
- Vol. 16 (1) , 59-73
Emerging Prevalence of Fatty Liver Disease in HIV
Fatty liver disease is a growing concern in people living with HIV, the main drivers are alcoholic liver disease and nonalcoholic fatty liver disease. It has shown to negatively impact HIV care con...
- 26 January 2021
- Published by Taylor & Francis in Future Virology
- Vol. 16 (1) , 59-73
Emerging Prevalence of Fatty Liver Disease in HIV
Fatty liver disease is a growing concern in people living with HIV, the main drivers are alcoholic liver disease and nonalcoholic fatty liver disease. It has shown to negatively impact HIV care con...
- Open Access
- 1 December 2020
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (12) , e2027551
Donor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation
Despite an increase in the number of liver transplants (LTs) performed in the United States, the rate at which patients are placed on the waitlist continues to surpass the increased number of transplants, creating a significant mismatch between organ supply and demand.1 The use of hepatitis C virus (HCV)–positive organs has been widely adopted as one of the solutions to the major organ shortage by increasing the donor pool.2 Although HCV infection is estimated to affect 1% to 2% of the general US population, this risk is higher (3%-18%) among organ donors with increased risk as defined by the Public Health Service.3 In light of the ongoing opioid epidemic and the associated rise in drug overdose deaths, the number of Public Health Service “increased risk” HCV-positive organs available has been increasing rapidly.4,5
- 1 December 2020
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 3 (12) , e2027551
Open AccessDonor Characteristics and Regional Differences in the Utilization of HCV-Positive Donors in Liver Transplantation
Despite an increase in the number of liver transplants (LTs) performed in the United States, the rate at which patients are placed on the waitlist continues to surpass the increased number of transplants, creating a significant mismatch between organ supply and demand.1 The use of hepatitis C virus (HCV)–positive organs has been widely adopted as one of the solutions to the major organ shortage by increasing the donor pool.2 Although HCV infection is estimated to affect 1% to 2% of the general US population, this risk is higher (3%-18%) among organ donors with increased risk as defined by the Public Health Service.3 In light of the ongoing opioid epidemic and the associated rise in drug overdose deaths, the number of Public Health Service “increased risk” HCV-positive organs available has been increasing rapidly.4,5
- 31 October 2020
- Published by Springer Nature
- p. 187-218
Viral Hepatitis Non: B, C, D and Acute and Acute on Chronic Liver Failure
Acute liver failure (ALF) and acute on chronic liver failure (ACLF) are two unique clinical syndromes associated with a high risk of mortality. Non-HBV/HCV/HDV viruses including the hepatotrophic viruses (HAV and HEV) and non-hepatotrophic viruses (EBV/CMV/VZV) are important causes of both syndromes. Diagnosis of ALF and ACLF relies on proper physician awareness especially in high risk populations and the correct testing in the setting of a compatible clinical picture. Prevention of certain viruses such as HAV and HEV in endemic populations with proper hygiene and vaccination is critical. Prognosis and management differs with each disease condition but includes supportive care for failing organ systems, virus directed treatment, and liver transplantation.
- 31 October 2020
- Published by Springer Nature
- p. 187-218
Viral Hepatitis Non: B, C, D and Acute and Acute on Chronic Liver Failure
Acute liver failure (ALF) and acute on chronic liver failure (ACLF) are two unique clinical syndromes associated with a high risk of mortality. Non-HBV/HCV/HDV viruses including the hepatotrophic viruses (HAV and HEV) and non-hepatotrophic viruses (EBV/CMV/VZV) are important causes of both syndromes. Diagnosis of ALF and ACLF relies on proper physician awareness especially in high risk populations and the correct testing in the setting of a compatible clinical picture. Prevention of certain viruses such as HAV and HEV in endemic populations with proper hygiene and vaccination is critical. Prognosis and management differs with each disease condition but includes supportive care for failing organ systems, virus directed treatment, and liver transplantation.
- 19 August 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (8) , 1311-1322
Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States
Summary: Background: Thrombocytopenia is the most common haematological abnormality in patients with chronic liver disease in the United States. Severe thrombocytopenia (platelet count 9/L) can complicate the management of patients with chronic liver disease by significantly increasing the potential risk of bleeding during or after invasive procedures. The current standard‐of‐care treatment for severe thrombocytopenia is platelet transfusion. Novel agents that target the thrombopoietin pathway, including receptor agonists avatrombopag and lusutrombopag, have recently shown promise in clinical trials as alternatives to platelet transfusion.Aim: To review treatment options for severe thrombocytopenia, including platelet transfusion and thrombopoietin‐receptor agonists, with the aim of producing a simplified treatment algorithm.Methods: Five liver disease specialists were assigned sections of the manuscript to research and present at a consensus meeting in April 2019, with the goal of creating an easy‐to‐use, effective treatment plan for severe thrombocytopenia in patients with chronic liver disease.Results: Through discussion and collaborative decision making, a simplified algorithm was developed to provide guidance to healthcare professionals on treating severe thrombocytopenia in patients with chronic liver disease undergoing elective medical procedures in the United States. As part of these guidelines, we outline the use of the US Food and Drug Administration‐approved thrombopoietin receptor agonists avatrombopag and lusutrombopag as well tolerated and effective alternatives to platelet transfusion.Conclusions: This algorithm provides guidance for the management of severe thrombocytopenia to reduce bleeding risks in patients with chronic liver disease undergoing elective procedures, while reducing requirement for platelet transfusion.
- 19 August 2020
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (8) , 1311-1322
Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States
Summary: Background: Thrombocytopenia is the most common haematological abnormality in patients with chronic liver disease in the United States. Severe thrombocytopenia (platelet count 9/L) can complicate the management of patients with chronic liver disease by significantly increasing the potential risk of bleeding during or after invasive procedures. The current standard‐of‐care treatment for severe thrombocytopenia is platelet transfusion. Novel agents that target the thrombopoietin pathway, including receptor agonists avatrombopag and lusutrombopag, have recently shown promise in clinical trials as alternatives to platelet transfusion.Aim: To review treatment options for severe thrombocytopenia, including platelet transfusion and thrombopoietin‐receptor agonists, with the aim of producing a simplified treatment algorithm.Methods: Five liver disease specialists were assigned sections of the manuscript to research and present at a consensus meeting in April 2019, with the goal of creating an easy‐to‐use, effective treatment plan for severe thrombocytopenia in patients with chronic liver disease.Results: Through discussion and collaborative decision making, a simplified algorithm was developed to provide guidance to healthcare professionals on treating severe thrombocytopenia in patients with chronic liver disease undergoing elective medical procedures in the United States. As part of these guidelines, we outline the use of the US Food and Drug Administration‐approved thrombopoietin receptor agonists avatrombopag and lusutrombopag as well tolerated and effective alternatives to platelet transfusion.Conclusions: This algorithm provides guidance for the management of severe thrombocytopenia to reduce bleeding risks in patients with chronic liver disease undergoing elective procedures, while reducing requirement for platelet transfusion.